Current treatment paradigms for advanced stage Hodgkin lymphoma
Current treatment paradigms for advanced stage Hodgkin lymphoma
The treatment of advanced classical Hodgkin Lymphoma (cHL) has evolved over the last 50 years with a progressive improvement in long term cure rates in patients up to the age of 60 years. However, a minority of these survivors experience severe morbidity and mortality resulting from intensive chemotherapy and radiotherapy, leading to a drive to de-escalate treatment without compromising survival. The early identification of patients with chemoresistant disease by functional imaging allows the modulation of therapy and an efficient means to test new agents in those most in need of more effective therapy. The outcomes of treatment for older patients have not improved at the same rate, and this group requires a different approach, incorporating specialist geriatric support to personalise therapy. Clinical trials that focus on quality of life, comorbidity and survival are needed to improve survival rates for this expanding population with complex needs.
advanced Hodgkin lymphoma, brentuximab vedotin, elderly patients, immune checkpoint inhibitors, response adapted therapy
Longley, Jemma
f9f57245-1b80-44ee-8775-0893d1b383c3
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Longley, Jemma
f9f57245-1b80-44ee-8775-0893d1b383c3
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Longley, Jemma and Johnson, Peter W.M.
(2018)
Current treatment paradigms for advanced stage Hodgkin lymphoma.
British Journal of Haematology.
(doi:10.1111/bjh.15622).
Abstract
The treatment of advanced classical Hodgkin Lymphoma (cHL) has evolved over the last 50 years with a progressive improvement in long term cure rates in patients up to the age of 60 years. However, a minority of these survivors experience severe morbidity and mortality resulting from intensive chemotherapy and radiotherapy, leading to a drive to de-escalate treatment without compromising survival. The early identification of patients with chemoresistant disease by functional imaging allows the modulation of therapy and an efficient means to test new agents in those most in need of more effective therapy. The outcomes of treatment for older patients have not improved at the same rate, and this group requires a different approach, incorporating specialist geriatric support to personalise therapy. Clinical trials that focus on quality of life, comorbidity and survival are needed to improve survival rates for this expanding population with complex needs.
Text
Treatment paradigms in advanced HL
- Accepted Manuscript
Text
Treatment paradigms in advanced HL
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 15 September 2018
e-pub ahead of print date: 8 November 2018
Keywords:
advanced Hodgkin lymphoma, brentuximab vedotin, elderly patients, immune checkpoint inhibitors, response adapted therapy
Identifiers
Local EPrints ID: 426455
URI: http://eprints.soton.ac.uk/id/eprint/426455
ISSN: 0007-1048
PURE UUID: 42af0279-57cc-444b-9c99-5de39dd26c32
Catalogue record
Date deposited: 28 Nov 2018 17:30
Last modified: 16 Mar 2024 07:21
Export record
Altmetrics
Contributors
Author:
Jemma Longley
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
